-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pixabay.
Pixabay.
Glutamate dysfunction is related to the pathophysiology of schizophrenia, but the nature of this dysfunction may change with the course of the disease.
This heterogeneity may be related to factors such as age, course of disease, severity of symptoms, use of illegal substances, and exposure to antipsychotic drugs.
In order to better describe the glutamatergic dysfunction in patients with schizophrenia, some researchers conducted a large-scale analysis of individual participants’ data, studying age, antipsychotic drug exposure, diagnosis , symptom severity and function, and glutamine The relationship between 1H-MRS measurements of acid energy metabolite levels.
The researchers searched the MEDLINE database to identify journal articles published between January 1, 1980 and June 3, 2020.
The researchers searched the MEDLINE database to identify journal articles published between January 1, 1980 and June 3, 2020.
Finally, 42 studies were included, including data on 1251 patients with schizophrenia (mean [SD] age 30.
The levels of glutamate metabolites in the medial frontal cortex (MFC) of patients and healthy volunteers by age
Patients and healthy volunteers Medial frontal cortex (MFC) glutamate metabolite levels by age Patients and healthy volunteers Medial frontal cortex (MFC) glutamate metabolite levels by age Patients and healthy volunteers Levels of glutamate metabolites in the medial frontal cortex (MFC) by ageCollectively, these results indicate that high Glu levels may be related to more serious diseases, but through effective antipsychotic treatment, Glu levels may be lowered below the levels observed in healthy volunteers.
Collectively, these results indicate that high Glu levels may be associated with more serious diseases, but through effective antipsychotic treatment, Glu levels may be reduced to levels lower than those observed in healthy volunteers.
These findings have important implications for MRS research in schizophrenia.
References: Merritt K, McGuire PK, Egerton A, 1H-MRS in Schizophrenia Investigators.
Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level :A Mega-analysis of Individual Participant-Level Data .
JAMA Psychiatry.
Published online April 21, 2021.
com/journals/jamapsychiatry/fullarticle/2778479" target="_blank" rel="noopener">doi:10.
1001/jamapsychiatry.
2021.
0380 References: Merritt K, McGuire PK, Egerton A, 1H-MRS in Schizophrenia Investigators.
Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level :A Mega-analysis of Individual Participant-Level Data .
JAMA Psychiatry.
Published online April 21, 2021.
com/journals/jamapsychiatry/fullarticle/2778479" target="_blank" rel="noopener">doi:10.
1001/jamapsychiatry.
2021.
0380 References: Merritt K, McGuire PK, Egerton A, 1H-MRS in Schizophrenia Investigators.
Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level :A Mega-analysis of Individual Participant-Level Data .
JAMA Psychiatry.
Published online April 21, 2021.
com/journals/jamapsychiatry/fullarticle/2778479" target="_blank" rel="noopener">doi:10.
1001/jamapsychiatry.
2021.
0380 : A Mega-analysis of Individual Participant-Level Data : JAMA Psychiatry.
com/journals/jamapsychiatry/fullarticle/2778479" target="_blank" rel="noopener">doi:10.
1001 /jamapsychiatry.
2021.
0380 Leave a message here
